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Marek’s disease virus (MDV) is a cell associated alphaherpesvirus that causes fatal
lymphoma in chickens. One factor that plays a crucial role in MDV pathogenesis is the
viral CXC chemokine vIL-8 that was originally named after chicken interleukin 8 (cIL-8).
However, a recent study demonstrated that vIL-8 recruits B cells and a subset of T cells
but not neutrophils, suggesting that vIL-8 is not a cIL-8 orthologue. In this study, we
set to identify the cellular orthologues and receptor of vIL-8 using in silico analyses,
binding and chemotaxis assays. Sequence and phylogenetic analyses of all chicken
CXC chemokines present in the recently published chicken genome revealed that vIL-8
shares the highest amino acid similarity with the CXCL13L1 variant. To evaluate if vIL-8
and CXCL13L1 are also functional orthologues, we assessed their binding properties
and chemotaxis activity. We demonstrated that both vIL-8 and CXCL13 variants bind B
cells and subsets of T cells, confirming that they target the same cell types. In addition,
the chemokines not only bound the target cells but also induced chemotaxis. Finally, we
identified CXCR5 as the receptor of vIL-8 and CXCL13 variants and confirmed that the
receptor is expressed on MDV target cells. Taken together, our data demonstrate the
conservation of the receptor-ligand interaction between CXCR5 and CXCL13 and shed
light on the origin and function of the MDV-encoded vIL-8 chemokine, which plays a
crucial role in the pathogenesis of this highly oncogenic virus.
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INTRODUCTION
Marek’s disease virus (MDV) is a highly oncogenic Alphaherpesvirus that infects chickens
and causes immense economic losses worldwide (Davison and Nair, 2004). It is also known
as gallid herpesvirus type 2 (GaHV-2) and causes a variety of clinical symptoms including
immunosuppression, paralysis and acute death (Witter, 1997). In addition,MDV efficiently induces
malignant T cell lymphomas, which are considered to be the most frequent clinically-diagnosed
cancer in the animal kingdom (Parcells et al., 2012). Infection of susceptible animals with virulent
MDV strains commonly results in a mortality of up to 100% (Davison and Nair, 2004). Current
MDV vaccines are highly effective in minimizing commercial losses but do not elicit a sterilizing
immunity, allowing a continued evolution of MDV strains in vaccinated chicken flocks (Davison
and Nair, 2005; Osterrieder et al., 2006).
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Upon inhalation of cell-free MDV from a contaminated
environment, the virus is able to infect macrophages, dendritic
cells (DCs) and B cells that transport the virus to lymphoid
organs such as the spleen, thymus and bursa of Fabricius,
where the virus can be detected within 24 h post-infection. In
infected chickens, MDV predominantly replicates in B cells that
subsequently transfer the virus to T cells (Jarosinski et al., 2006).
The virus can either productively replicate in T cells or establish
latency, allowing the virus to persist in the host for life (Jarosinski
et al., 2006; Schermuly et al., 2015). In addition, MDV can
transform CD4+ T cells, resulting in deadly lymphomas. MDV-
induced tumor cells are often clonal within an animal and have
a regulatory T cell (Treg) phenotype based on their cytokine and
cell surface marker profiles including CD25 and CD30 (Burgess
et al., 2004; Shack et al., 2008). In addition, these transformed
cells harbor the integrated viral genome in one or multiple
chromosomes (Kaufer et al., 2011b; Greco et al., 2014; Osterrieder
et al., 2014), which ensures maintenance of the virus genome in
these rapidly dividing cells. Several viral factors have been shown
to be involved in the transformation process, including the major
oncogene Meq (Jones et al., 1992), the virus-encoded telomerase
RNA vTR (Kaufer et al., 2010, 2011a), miRNAs (Yao et al., 2009;
Zhao et al., 2011) and several putative ORFs of unknown function
(Jarosinski et al., 2005; Jarosinski and Schat, 2006).
Another factor that plays a crucial role in MDV pathogenesis
and tumor formation is the CXC chemokine vIL-8 (Parcells et al.,
2001; Engel et al., 2012). The MDV genome encodes two copies
of vIL-8 that was originally named after interleukin 8 (cIL-8;
cCXCL8), the first CXC chemokine identified in chicken (Kaiser
et al., 1999; Parcells et al., 2001). vIL-8 is secreted by MDV
infected cells and is essential for the establishment of infection
in animals infected via the natural route. The viral chemokine
was initially described as a chemoattractant of chicken peripheral
blood mononuclear cells (PBMCs) (Parcells et al., 2001). Recent
studies revealed that vIL-8 recruits B cells, the main target for
MDV lytic replication. In addition, vIL-8 interacts with CD4+
CD25+ T cells that likely serve as a target for MDV latency and
transformation (Engel et al., 2012).
The biological properties of vIL-8 are in stark contrast to
the functions of its putative cellular IL-8 orthologues. IL-8
binds and recruits neutrophils instead of B or T cells (Kaiser
et al., 2005), suggesting that IL-8 is not the cellular orthologue
of the viral chemokine. Since the release of the complete
chicken genome, eight chicken CXC chemokine orthologues
have been identified (Kaiser et al., 2005). Amongst are the
three inflammatory chemokines CXCL8L1 (K60), CXCL8L2
(9E3/CEF4) and CXCL1 (GROa) that possess a conserved ELR
(glutamic acid–leucine–arginine) motif (Li et al., 2005; Poh
et al., 2008). The other five are homeostatic ELR-negative CXC
chemokines that coordinate leukocyte trafficking throughout the
body. These include CXCL12, CXCL14 and three related genes
named CXCL13L1, L2, and L3 (Kaiser et al., 2005).
Here, we performed sequence and phylogenetic analysis to
identify potential cellular orthologues of vIL-8. The functional
Abbreviations:MDV,Marek’s disease virus; IL-8, interleukin 8; PBMCs, peripheral
blood mononuclear cells.
properties of vIL-8 and its closest relatives were assessed using
binding and chemotaxis assays. Beyond that, we identified the
receptor of vIL-8 and its cellular orthologues and confirmed
receptor expression on the natural target cells of vIL-8.
MATERIALS AND METHODS
Sequence and Phylogenetic Analyses
Amino acid sequences of MDV vIL-8 and all known chicken
CXC chemokines were aligned using the ClustalW (Vector
NTI 9.1, Invitrogen) and MEGA 6 software (Tamura et al.,
2013). Phylogenetic analyses of vIL-8, chicken and human
CXC chemokines were performed based on their amino acid
sequences applying neighbor-joining (NJ), maximum-parsimony
(MP), and maximum-likelihood (ML) methods using the MEGA
6 software (Tamura et al., 2013). Full length amino acid
sequences of MDV vIL-8 (AAN60433.1), the known chicken
CXC chemokines, cCXCL1 (XP_420608.1), cCXCL8L1 (NP_
990349.1), cCXCL8L2 (NP_990829.1), cCXCL12 (NP_989841.1),
CXCL13L1 (XP_004941081.1), CXCL13L2 (CCC15119.1),
CXCL13L3 (CCC15120.1), cCXCL14 (NP_990043.1) and
human CXC chemokine orthologues, hCXCL1 (AAH11976.1),
hCXCL8 (NP_000575.1), hCXCL12 (AAH39893.1), hCXCL13
(AAH12589.1), hCXCL14 (XP_527018.2) were obtained from
Genbank.
Cells
Cells for flow cytometric analysis were obtained from M11
(Bx2x/ Bx2x) white leghorn chicken. Birds were housed
under conventional conditions in groups of up to 10 birds.
All animal experiments were approved by the appropriate
governmental agencies (Regierung von Oberbayern, Az.: 55.2-
1-54-2532.6-12-09). HEK293 and HEK293-T cells were grown
in DMEM high glucose supplemented with 10% FBS and 1%
penicillin/streptomycin (Biochrom, Germany), DT40 cells were
grown in IMDM (Biochrom, Germany) with 10% FBS, 1%
chicken serum (ThermoFisher Scientific, USA) and 1mM ß-
Mercaptoethanol at 37◦C. Primary leukocytes were obtained by
dissociation of the organs using a stainless steel sieve and density
centrifugation on Biocoll (1,077 g/ml, Biochrom, Germany).
Generation of Recombinant Chemokines
To generate recombinant proteins for binding and chemotaxis
assays, expression plasmids were generated. Full-length coding
sequences of MDV-vIL-8, CXCL13L1, L2, or L3 were cloned into
a modified pCR3.1 expression vector containing a C-terminal
huFc-tag. cDNA from RB-1B infected cells or spleen cells of
a Rhode Island Red (RIR) chicken served as a template for
cloning the viral and cellular genes, respectively. HEK293 cells
were transfected with the expression plasmids constructs using
polyethyleneimine (PEI) as described previously (Boussif et al.,
1995) or X-tremeGENE R© 9 DNA transfection reagent (Sigma-
Aldrich) according to the manufacturer’s protocol. To generate
protein for chemotaxis assays, cells were cultured in serum
free HEK293A medium (Bio&SELL, Germany). Supernatants
containing the secreted huFc tagged chemokines or huFc control
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FIGURE 1 | Sequence and phylogenetic analyses. (A) Amino acid sequence alignment of vIL-8 and chicken CXC chemokines was performed using Clustal W. The
CXC and the ELR motif are indicated by asterisks and a box, respectively. Conserved cysteine and proline residues are highlighted with black shades. Conserved
amino acid residues with vIL-8 are shown in dark gray and similar residues in light gray. Alignment gaps are indicated by dashes. (B) Phylogenetic tree of vIL-8,
chicken (c) and related human (h) CXC chemokines. The human and chicken ELR-positive inflammatory CXC chemokines are indicated.
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protein were harvested after 24 h and subjected to further
analysis.
Confirmation of Recombinant Chemokines
Recombinant chemokines and huFc control were quantified
by ELISA. Briefly, 96-well ELISA plates (MaxiSorp, Nunc,
Wiesbaden, Germany) were coated overnight with 1µg/ml of
donkey anti-huIgG (Jackson ImmunoResearch Europe Ltd, UK)
in carbonate buffer (pH 9.6) and blocked with 4% skim milk.
Plates were then incubated with serial dilutions of supernatants
containing huFC-tagged chemokines, followed by incubation
with HRP coupled rabbit anti-huIgG (SouthernBiotech, USA)
1:4,000 in PBS-T and tetramethylbenzidine (TMB). To confirm
the correct size of the recombinant chemokines and huFc control
protein we performed SDS-PAGE and Western blotting using a
goat anti-human Fc HRP-conjugated secondary Ab (Invitrogen).
Generation of CXCR5 Expressing Cells and
a Monoclonal Anti-CXCR5 Antibody
To generate cell lines expressing CXCR5 with an N-terminal
extracellular Flag-tag, we amplified the full-length receptor
from cDNA of bursal cells and cloned it into the p3XFLAG-
myc-CMVTM-25 expression vector (Sigma, USA). The CXCR5
expression plasmid was transfected into HEK293 cells using
X-tremeGENE R© 9 DNA transfection reagent (Sigma-Aldrich)
according to the manufacturer’s protocol and stable clones were
selected with 250µg/ml of neomycin (Biochrom, Germany).
Receptor expression was confirmed by flow cytometry using an
Alexa647 conjugated mouse anti-Flag antibody (AbD Serotec,
Germany).
CXCR5 expressing HEK293 cells were used for repeated
intraperitoneal immunizations of a BALB/c mouse. Murine
spleen cells were fused to SP2/0-Ag14 hybridoma cells. Specificity
of resulting hybridomas was examined by flow cytometry using
undiluted hybridoma supernatant and goat anti-mouse-IgG-
FITC (Sigma-Aldrich, USA, 1:200) on primary spleen cells as
well as HEK293-CXCR5 cells and untransfected HEK293. Clone
6A9 was selected, its isotype was determined as IgG1 and
monoclonality was ensured by subcloning using the single-cell
limited dilution method.
Binding Assays
Receptor binding of recombinant chemokines was examined by
flow cytometry on the chicken B cell line DT40 cells, HEK293-
CXCR5 cells and primary chicken leukocytes from different
lymphoid organs. Cells were incubated on ice with chemokine
containing supernatants for 30min. Chemokine binding was
detected using a mouse anti-huFC-Alexa647 secondary antibody.
Subpopulations of primary leukocytes were assessed by staining
with RPE conjugated anti-Bu1 (clone AV20, B cells), anti-CD4
(CT4), anti-CD8 (CT8) and anti-Kul01 (myeloid cells) (Southern
Biotechnology, USA).
Migration Assays
Migration assays were performed at room temperature with
endotoxin-free single-use material. DT40 cells were washed
twice in warm RPMI (Biochrom, Germany) and seeded at a
FIGURE 2 | Expression of recombinant CXCL13 proteins. (A) Quantification of
the indicated recombinant chemokines and the huFc control protein by ELISA.
BCMA-Fc and media from mock transfected cells were used as positive and
negative controls, respectively. (B) Western blot analysis of the indicated
recombinant chemokines and the huFc control protein.
concentration of 105 cells/ml in chemotaxis medium (RPMI
containing 0.5% bovine serum albumin). Twenty-four-well-
Transwell R© Permeable Supports (Corning, New York, USA)
with a pore size of 5µm were coated with bovine fibronectin
(10µg/ml) (Life Technologies) dissolved in endotoxin-free
distilled H2O (Sigma-Aldrich) and incubated for 1 h at 37
◦C
and 5% CO2. Plates were air-dried at 37
◦C for 2 h. Different
dilutions of serum free supernatant from chemokine-transfected
HEK293-T cells were added to the bottom of the transwell
inserts. Chemotaxis medium served as a control. 100 µl of
DT40 cell suspension was added to the transwell inserts. After
a migration time of 90min, cells were taken from the lower
chamber and transferred directly into FACS Trucount R© tubes
(Becton Dickinson) and the number of cells was determined
by flow cytometry. The chemokinesis index was calculated by
dividing the number of migrated cells in stimulated wells by the
chemokinesis control.
Flow Cytometry
Flow cytometric analyses were performed with a BD FACSCanto
II (Becton Dickinson, Heidelberg, Germany) using DIVA and
FlowJo (Tree Star Inc., Oregon, USA) software. Plots were gated
for viable cells upon doublet discrimination.
Statistics
Statistical analyses were performed using GraphPad Prism.
Binding assays data of were analyzed using paired Student’s
t-test and migration assays by One-way ANOVA. Results were
considered significant when p < 0.05.
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FIGURE 3 | Functional analysis of vIL-8 and CXCL13 variants. (A) Binding of indicated chemokines to DT40 cells was assessed by FACS. One representative
experiment of three independent experiments is shown. (B) Quantification of chemokine binding to DT40 cells shown in (A). Mean ± SD of mean fluorescence
intensity (MFI) of three independent experiments are shown. (C) Recruitment of DT40 cells was assessed by chemotaxis assays. Migration of B cells was assessed at
three different dilutions as indicated. Shown are mean ± SD of four replicates out of two independent experiments.
RESULTS
Sequence and Phylogenetic Analyses of
MDV vIL-8
To identify potential cellular orthologs of the viral chemokine,
we analyzed the amino acid sequences of all chicken CXC
chemokines present in the recently published chicken genome
(Figure 1A). Surprisingly, vIL-8 had the highest homology to
the CXCL13 variants and not the two chicken IL8 chemokines
CXCL8L1 (K60) and CXCL8L2 (9E3/CEF4) it was initially named
after. CXCL13L1 shared the highest sequence identity of 53.8%
with vIL-8, suggesting that this variant is the true orthologue
of the viral chemokine. CXCL13L2 (33.0%) and CXCL13L3
(36.1%) also shared a higher sequence identity with vIL-8,
compared to the IL-8 variants CXCL8L1 (28.8%) and CXCL8L2
(31.1%). Importantly, vIL-8 and all three CXCL13 variants lack
the conserved ELR motif present in granulocyte attracting,
inflammatory chemokines such as IL-8. Furthermore, vIL-8,
CXCL13L1, and CXCL1L2 are the only genes with three exons,
while all other chicken CXC chemokines have four exons (Wang
et al., 2005). In addition, we performed phylogenetic analyses of
vIL-8 and cellular CXC chemokines (Figure 1B), in which vIL-
8 clustered with the human and the chicken CXCL13 variants
and not the inflammatory IL-8 chemokines, again indicating that
vIL-8 is a CXCL13 orthologue.
vIL-8 Is the Functional Ortholog of
CXCL13L1
To confirm the in silico analysis, we compared the biological
properties of vIL-8 and the chicken CXCL13 variants. To
obtain functional chemokines, we cloned huFC-tagged vIL-8
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FIGURE 4 | Interaction of vIL-8 and CXCL13 variants with primary lymphocytes. Binding of the indicated chemokines to (A) B and (B) T helper cells in primary PBMCs.
Cells were stained with anti-Bu1 or anti-CD4 and the indicated chemokines and plots gated for leukocytes. Data represent one of two independent experiments.
and CXCL13 variants into expression plasmids and produced
recombinant proteins in HEK293 cells. Recombinant protein
in culture supernatants was quantified by ELISA (Figure 2A).
Western blot analysis confirmed the correct size of the
monomeric form of CXCL13L1, L2, and L3 of approximately
38 kDa (Figure 2B). For CXCL13L1, an additional lower
molecular weight band was observed that most likely represents
a degradation product of the chemokine. As observed previously,
the size of huFC and vIL-8 was larger than predicted (Engel
et al., 2012), which is likely due to glycosylation of the
proteins.
We previously demonstrated that vIL-8 binds to and
induces chemotaxis of B cells (Engel et al., 2012). Therefore,
we assessed the binding of the recombinant chemokines to
the chicken B cell line DT40. vIL-8 and all three CXCL13
variants efficiently bound to chicken B cells (Figures 3A,B),
while no binding was observed for the control protein.
Interestingly, vIL-8 showed a clearly higher MFI than the
CXCL13 variants.
To determine if vIL-8 and the CXCL13 variants induce B cell
migration, we performed chemotaxis assays using DT40 cells.
vIL-8 and the CXCL13 variants efficiently induced chemotaxis
(Figure 3C), suggesting that these chemokines have similar
biological functions.
To confirm that vIL-8 and the CXCL13 variants also target the
same cell types in vivo, we performed binding assays with primary
PBMCs. vIL-8, CXCL13L1 and CXCL13L2 bound to Bu1 positive
B cells (Figure 4A), indicating that these chemokines also target
the same cells in vivo. As on DT40 cells, strongest binding
was observed for vIL-8. Surprisingly, CXCL13L3 did not bind
primary B cells. In addition to B cells, vIL-8 was also previously
shown to bind a certain subset of CD4+ T cells (Engel et al.,
2012). Therefore, we assessed binding of vIL-8 and the CXCL13
variants to CD4+ T cells in primary PBMCs. vIL-8, CXCL13L1
and CXCL13L2 bound to a subpopulation of CD4+ T cells. As
observed for B cells, vIL-8 bound these cells more efficiently
than the cellular chemokines, while only minimal binding was
observed for CXCL13L3 (Figure 4B). Taken together, our data
demonstrate that vIL-8 has binding and chemotaxis properties
comparable to CXCL13L1 and CXCL13L2, further supporting
our in silico data that the viral chemokine is a CXCL13 ortholog.
CXCR5 Is a Receptor of Both vIL-8 and
CXCL13
Next, we set to determine the receptor of vIL-8 and its cellular
orthologs. In humans and mice, CXCL13 has only a single
receptor, CXCR5. Hence we examined whether the chicken
CXCL13 orthologs bind to the recently discovered chicken
CXCR5 (DeVries et al., 2006). Therefore, we generated HEK293
cells that express the receptor with an N-terminal Flag-tag
and used these cells to produce a monoclonal antibody against
chicken CXCR5, which stains HEK293-CXCR5 as well as an anti-
Flag positive control (Figure 5A). To assess binding of vIL-8
and CXCL13 variants, CXCR5 expressing cells were mixed with
parental cells at a 1:2 ratio as an internal control for binding
specificity. As the anti-CXCR5 antibody, vIL-8 efficiently bound
the CXCR5 expressing cells but not the control cells (Figure 5B),
demonstrating that CXCR5 is the receptor of the viral chemokine.
Similarly, all three CXCL13 variants interacted with CXCR5,
highlighting that this receptor-ligand pair is conserved from
mammals to chickens.
Next, we assessed if the CXCR5 is expressed on the natural
target cells of MDV in vivo. We isolated primary cells from blood
and different lymphoid tissues and detected CXCR5 expression
using our CXCR5 antibody. CXCR5 was efficiently expressed
on B cells and a subset of CD4+ cells as shown for vIL-8
(Figure 5C). In addition, we assessed CXCR5 expression in cells
isolated from blood (Figure S1A), spleen (Figure S1B), bursa of
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FIGURE 5 | CXCR5 is the receptor for vIL-8 and CXCL13 variants. (A) The specificity of the newly generated mouse-anti-cCXR5 antibody (clone 6A9) was assessed
by FACS on Flag-CXCR5 expressing and control HEK293 cells. (B) Binding of the indicated chemokines to a mixture of CXCR5 expressing HEK293 and
untransfected parental cells (ratio 1:2). The huFc protein and CXCR5-specific antibody were used as negative and positive control, respectively. (C) Detection of the
CXCR5 receptor on the target cells of vIL-8 and CXCL13 variants. Primary PBMCs were stained for B (Bu-1) or T helper cells (CD4) and the CXCR5 specific antibody.
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Fabricius (Figure S1C) and thymus (Figure S1D). CXCR5 was
found on all mature B cells in the spleen and all immature B
cells in the Bursa of Fabricius. Very few CXCR5 positive T cells
were observed in the blood, while about 10% of splenic CD4
and CD8 positive cells do express CXCR5. Among thymic T
cells, CXCR5 expression is limited to small subpopulations of
CD4 and CD8 single positive cells. Intriguingly, all KUL01+
monocytes in the blood and most of the KUL01+ macrophages
in the spleen do also express CXCR5, suggesting the vIL-8 could
also recruit these cells for MDV infection. Taken together, our
data demonstrate that CXCR5 is the receptor of vIL-8 and
CXCL13 and is expressed by B cells, CD4+ T cell subsets and
monocytes /macrophages.
DISCUSSION
Herpesviruses co-evolved with their host over millions of
years. During this time, many herpesviruses acquired host cell
proteins that aid in the virus lifecycle by mediating immune
evasion, cell proliferation or apoptosis control (Holzerlandt et al.,
2002). In addition, several herpesvirus genomes encode viral
chemokines that can induce or inhibit chemotaxis (Epperson
et al., 2012; Cornaby et al., 2016). MDV acquired a CXC
chemokine that was named vIL-8 due to its similarity to IL-
8 (9E3/CEF4), the first CXC chemokine identified in chickens
(Kaiser et al., 1999; Parcells et al., 2001). Since then, several other
chicken CXC chemokines have been discovered in the complete
chicken genome (International Chicken Genome Sequencing
Consortium, 2004). Investigation of the biological functions of
vIL-8 revealed that the virus chemokine binds and recruits
different target cells than IL-8. Therefore, we set to identify the
cellular ortholog of vIL-8 and compare their biological properties.
In silico analyses provided the first evidence that vIL-8 is an
ortholog of CXCL13, and not the inflammatory chicken IL-
8 chemokines. The absence of the ELR motif and the exon
structure also indicated that vIL-8 was derived from one of the
CXCL13 variants, most likely CXCL13L1 and CXCL13L2. While
CXCL13L1 shared the highest sequence similarity with vIL-8,
the other two CXCL13 variants also possess similar biological
properties. Binding and induction of chemotaxis of B cells
(DT40) was comparable between vIL-8 and the CXCL13 variants.
We used primary B and T cells in PBMCs to confirm that
the binding also occurs to cells ex vivo. While CXCL13L1 and
CXCL13L2 bound B and T cells in a manner comparable to
vIL-8, CXCL13L3 showed no or only minimal binding. One
possible reason for the reduced binding of the L3 variant is a
lower stability of the chemokine. This could also explain the
consistently lower yield of CXCL13L3 compared to the other
chemokines as detected by ELISA. Alternatively, the amount of
CXCR5 expressed on 293 cells vs. B and T cells could contribute
to this phenomenon. Intriguingly, in both binding and migration
assays, performance of vIL-8 seemed to exceed the cellular
orthologs. Possibly, the viral chemokine has evolved an even
higher affinity compared to its cellular orthologs to preferentially
attract MDV target cells.
Only one CXCL13 chemokine is present in the genome of
human and mice that binds to the CXCR5 receptor (Cyster et al.,
2000). CXCR5 is mainly expressed on B cells, T helper cells
and follicular helper T cells. Interaction between the homeostatic
chemokine and its single receptor is central for the guidance of
B cells to B cell follicles and has part in the zoning of Germinal
Centers (Russo et al., 2014). It also attracts helper T cells to B cell
areas and mediates the interaction between B and T cells.
In chickens, it remained unknown if the three CXCL13
variants also bind the putative orthologue of the CXCR5 receptor.
Therefore, we generated a monoclonal antibody against CXCR5,
addressed its expression on chicken lymphocytes and could
demonstrate that all B cells and subsets of T cells have the
receptor on their surface. Intriguingly these subsets are also
targeted by vIL-8 and the CXCL13 variants. As vIL-8 and all
CXCL13 variants efficiently bound to CXCR5 expressing cells,
but not the control cells, we could confirm that chicken CXCR5
is the receptor for these chemokines. Recently it was shown,
that macrophages are also a potential target for MDV infection
(Chakraborty et al., 2017). Secretion of vIL-8 could allow the
recruitment of CXCR5 expressing monocytes and macrophages
to the site of infection that could transport the virus to lymphoid
organs where B and T cells are infected.
Taken together, we analyzed vIL-8 and all annotated chicken
CXC chemokines and identified the closest cellular orthologs.
Our data demonstrates that vIL-8 has biological functions
comparable to the CXCL13 variants and is most closely related
to the CXCL13L1. In addition, we identified chicken CXCR5 as
cellular receptor of this viral chemokine and its cellular orthologs.
Our data thereby provide the first functional evidence that
the chemokine-receptor pair CXCL13-CXCR5 is also conserved
between mammals and an avian species. All in all, our data not
only sheds light on the origin of the viral chemokine, but also
provides important insights into themechanism that allows vIL-8
to contribute to MDV pathogenesis.
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Figure S1 | Leukocytes were isolated from blood (A), spleen (B) and bursa of
Fabricius (C), stained with an anti-CXCR5 antibody and markers for different cell
populations for flow cytometric analysis. (D) Cells from the thymus were subjected
to a triple staining with anti-CD4, anti-CD8 and anti-CXCR5 and CD8 single
positive (Q1), CD4/CD8 double positive (Q2), CD4 single positive (Q3) and double
negative (Q4) cells were gated for CXCR5 expression.
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